🔎 Trials Near Me

Home › Alpha-1 Antitrypsin Deficiency › NCT01851642

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

RecruitingObservational studyHealthy volunteers welcome

The Role of Conformational Diseases on Macrophage Function

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

* Signed informed consent
* Male or female 18 years of age or older
* Negative pregnancy test for women of childbearing potential
* Hemoglobin \>12.5 g/dl measured on the day of participation
* Negative urine nicotine test

Exclusion Criteria:

* Pregnancy or breastfeeding
* Weight \< 50 kg
* History of anemia requiring blood transfusions, erythropoietin supplementation, or iron supplementation within the past 36 months
* Known hemoglobin \<12.5 g/dl within the past 90 days
* Systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \>100 mmHg
* Poor venous access
* Large volume blood donation (\>200 ml or 7 ounces) within the previous 56 days (e.g. blood donation for the purposes of blood banking)
* Clinically significant cardiac, hemostatic or neurological impairment or any other significant medical condition that, in the opinion of the investigator would affect subject safety (e.g., recent myocardial infarction, history of prolonged bleeding time, cerebral vascular accident, advanced cancer or uncontrolled medical condition)
* Psychiatric or cognitive disturbance or illness that would affect subject safety
* Current smoker

About the study

The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.

What is being tested

Sponsor: University of Florida · Participants: 220 · Started: Aug 9, 2007

Contact the study team

Official record on ClinicalTrials.gov — NCT01851642

Locations in the U.S.

FloridaShands at the University of Florida, Gainesville

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.